,trastuzumab deruxtecan
daiichi sankyo,astrazeneca
[]
live from #asco2022: t-dxd found to have a statistically significant increase in confirmed orr in pts intolerant to 1l gemcitabine. further study of the drug called for but results demonstrate potential to be a treatment for aggressive her2+ btc! 
Real time, on-demand personalized cancer education and support through our online educational platform